Toxicity of breast cancer treatment can be a marker of its success (ATAC trial)

October 29, 2008

The occurrence of hot flushes, cold and night sweats (vasomotor symptoms), and joint symptoms in breast cancer patients receiving endocrine treatment can indicate a reduced chance of cancer recurrence and thus act as a marker for treatment success. These are the conclusions of an Article published early Online and in the December edition of The Lancet Oncology, written by Professor Jack Cuzick, Cancer Research UK and Queen Mary School of Medicine and Dentistry, London, UK, and colleagues.

During endocrine treatment for breast cancer, the occurrence of the above symptoms, related to oestrogen depletion or oestrogen blockage, could indicate success of the treatment. In this study, women with hormone-receptor-positive tumours who reported these symptoms at the first follow-up visit in the ATAC* trial (which assessed tamoxifen or anastrozole for adjuvant therapy of post-menopausal breast cancer) were compared with women without these symptoms to see if there was a relationship between the symptoms and recurrence.

The researchers found that 37.5% of eligible women reported newly emergent vasomotor symptoms at the 3-month follow-up visit. These women had lower recurrence than those who did not report new vasomotor symptoms, with the 9-year recurrence rate reduced from 23% in women without symptoms to 18% in those with them. A greater decrease in breast cancer recurrence was seen for the 31.4% of eligible women who reported new joint symptoms at the 3-month follow-up visit compared with women not reporting these symptoms -- from 23% to 14%. These differences were seen with both tamoxifen and anastrozole; patients receiving anastrozole had lower recurrence rates than those receiving tamoxifen, both among women with and without symptoms

The authors conclude: "The appearance of new vasomotor symptoms or joint symptoms within the first 3 months is a useful biomarker, suggesting a greater response to endocrine treatment compared with women without these symptoms. Awareness of the relation between early treatment-emergent symptoms and beneficial response to therapy might be useful when reassuring patients who present with them, and might help to improve long-term treatment adherence when symptoms cannot be alleviated."
For Professor Jack Cuzick, Cancer Research UK and Queen Mary School of Medicine and Dentistry, London, UK, please contact Sally Staples T) +44 (0) 20 7061 6300 E) /

For full Article, see:

Please note this is a LANCET ONCOLOGY study, please credit it correctly

Notes to editors: *ATAC = Arimidex, Tamoxifen, Alone or in Combination trial


Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to